PROM1 and neoplasm: To assess the in vivo anti-tumor effect, CD133-targeted OAd (3 × 109 or 1 × 1010 vp/tumor) was then injected intratumorally into xenografts established with LoVo cells when the tumors reached 5–7 mm diameter.